非诺贝特联合贝那普利治疗扩张型心肌病并发慢性心力衰竭的临床研究  

Effect of combined fenofibrate and benazepril on dilated cardiomyopathy with chronic heart failure

作　　者：陈红霞[1] 刘如泉[1] 赵丽斌[1] 

机构地区：[1]武汉市汉口医院总院区心内科心功能室,武汉430012

出　　处：《临床心血管病杂志》2014年第2期108-110,共3页Journal of Clinical Cardiology

摘　　要：目的:观察非诺贝特联合贝那普利对扩张型心肌病并发慢性心力衰竭的临床疗效。方法:将62例患者随机分成对照组和观察组,对照组给予常规心力衰竭治疗(地高辛、利尿剂、β受体阻滞剂)及贝那普利,观察组在对照组基础上加服非诺贝特。随访患者120d,主要观察指标:NYHA分级、左心室射血分数(LVEF)、左室舒张末期内径(LVEDD)、三酰甘油(TG)及血尿酸(BUA)等。结果:治疗后120d,两组NYHA分级、LVEF、LVEDD均较治疗前明显改善(均P<0.05);与对照组相比,观察组NYHA分级、LVEF、LVEDD及TG、BUA水平改善更明显(均P<0.05)。结论:非诺贝特联合贝那普利能够改善扩张型心肌病并发心力衰竭的预后,延缓慢性心力衰竭的发展。Objective：To observe the effects of Fenofibrate and Benazepril on DCM（Dilated Cardiomyopathy） with chronic heart failure.Method：The 62patients with DCM and chronic heart failure were divided randomly into A group（control group,n=31,only treated with digitoxin,βreceptor blocker and Benazepril）,and B group（test group,n=31,treated with Fenofibrate more than A group）.Result：After 120days of treatment,NYHA,LVEF, LVEDD,TG and BUA are improved more significantly in the patients of B group than those of A group.Conclusion：Fenofibrate and Benazepril could improve the prognosis of the patients with DCM and chronic heart failure and delay the development of chronic heart failure.

关 键 词：扩张型心肌病 心力衰竭 非诺贝特 贝那普利 

分 类 号：R542.2[医药卫生—心血管疾病]